JP2019516350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516350A5 JP2019516350A5 JP2018550787A JP2018550787A JP2019516350A5 JP 2019516350 A5 JP2019516350 A5 JP 2019516350A5 JP 2018550787 A JP2018550787 A JP 2018550787A JP 2018550787 A JP2018550787 A JP 2018550787A JP 2019516350 A5 JP2019516350 A5 JP 2019516350A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polynucleotide
- seq
- lymphoma
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 33
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 6
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 10
- -1 CD8alpha Proteins 0.000 claims 7
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 208000007452 Plasmacytoma Diseases 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 3
- 102100038078 CD276 antigen Human genes 0.000 claims 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 3
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 3
- 102100022339 Integrin alpha-L Human genes 0.000 claims 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims 3
- 206010053869 POEMS syndrome Diseases 0.000 claims 3
- 102100029197 SLAM family member 6 Human genes 0.000 claims 3
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 210000004180 plasmocyte Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 102100024263 CD160 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 2
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 claims 2
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims 2
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 claims 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 claims 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 101000633782 Homo sapiens SLAM family member 8 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 102100025323 Integrin alpha-1 Human genes 0.000 claims 2
- 102100032818 Integrin alpha-4 Human genes 0.000 claims 2
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 2
- 102100039904 Integrin alpha-D Human genes 0.000 claims 2
- 102100022341 Integrin alpha-E Human genes 0.000 claims 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims 2
- 102100022297 Integrin alpha-X Human genes 0.000 claims 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 102100029214 SLAM family member 8 Human genes 0.000 claims 2
- 102100027744 Semaphorin-4D Human genes 0.000 claims 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- ZUXNHFFVQWADJL-UHFFFAOYSA-N 3,4,5-trimethoxy-n-(2-methoxyethyl)-n-(4-phenyl-1,3-thiazol-2-yl)benzamide Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1N(CCOC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZUXNHFFVQWADJL-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 101100481032 Arabidopsis thaliana TGA6 gene Proteins 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 108010056102 CD100 antigen Proteins 0.000 claims 1
- 108010017009 CD11b Antigen Proteins 0.000 claims 1
- 102100038077 CD226 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 claims 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 1
- 101000830594 Homo sapiens Tumor necrosis factor ligand superfamily member 14 Proteins 0.000 claims 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010041100 Integrin alpha6 Proteins 0.000 claims 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 claims 1
- 102100033016 Integrin beta-7 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108091008877 NK cell receptors Proteins 0.000 claims 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 102100029198 SLAM family member 7 Human genes 0.000 claims 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 102100026497 Zinc finger protein 654 Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 230000001707 blastogenic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 17
- 238000003501 co-culture Methods 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 9
- 230000001461 cytolytic effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 102100025674 Angiopoietin-related protein 4 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101000693076 Homo sapiens Angiopoietin-related protein 4 Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031538A JP7379561B2 (ja) | 2016-04-01 | 2022-03-02 | キメラ抗原及びｔ細胞受容体、並びに使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317258P | 2016-04-01 | 2016-04-01 | |
| US62/317,258 | 2016-04-01 | ||
| PCT/US2017/025351 WO2017173256A1 (en) | 2016-04-01 | 2017-03-31 | Chimeric antigen and t cell receptors and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031538A Division JP7379561B2 (ja) | 2016-04-01 | 2022-03-02 | キメラ抗原及びｔ細胞受容体、並びに使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516350A JP2019516350A (ja) | 2019-06-20 |
| JP2019516350A5 true JP2019516350A5 (enExample) | 2020-05-07 |
| JP7034934B2 JP7034934B2 (ja) | 2022-03-14 |
Family
ID=59960588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550787A Active JP7034934B2 (ja) | 2016-04-01 | 2017-03-31 | キメラ抗原及びｔ細胞受容体、並びに使用方法 |
| JP2022031538A Active JP7379561B2 (ja) | 2016-04-01 | 2022-03-02 | キメラ抗原及びｔ細胞受容体、並びに使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031538A Active JP7379561B2 (ja) | 2016-04-01 | 2022-03-02 | キメラ抗原及びｔ細胞受容体、並びに使用方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10603380B2 (enExample) |
| EP (2) | EP3436079B1 (enExample) |
| JP (2) | JP7034934B2 (enExample) |
| KR (2) | KR102427334B1 (enExample) |
| CN (1) | CN109328074A (enExample) |
| AR (2) | AR108427A1 (enExample) |
| AU (2) | AU2017240667C1 (enExample) |
| BR (1) | BR112018070073A2 (enExample) |
| CA (1) | CA3019149A1 (enExample) |
| CL (2) | CL2018002762A1 (enExample) |
| CO (1) | CO2018010453A2 (enExample) |
| CR (1) | CR20180461A (enExample) |
| CU (1) | CU20180121A7 (enExample) |
| DO (1) | DOP2018000213A (enExample) |
| EA (1) | EA201891965A1 (enExample) |
| EC (1) | ECSP18073833A (enExample) |
| ES (1) | ES2891578T3 (enExample) |
| IL (2) | IL303785A (enExample) |
| MX (2) | MX391308B (enExample) |
| PE (1) | PE20190173A1 (enExample) |
| PH (1) | PH12018550163A1 (enExample) |
| PL (1) | PL3436079T3 (enExample) |
| PT (1) | PT3436079T (enExample) |
| SA (1) | SA518400135B1 (enExample) |
| SG (2) | SG10201912489QA (enExample) |
| SI (1) | SI3436079T1 (enExample) |
| SV (1) | SV2018005756A (enExample) |
| TW (3) | TWI787599B (enExample) |
| WO (1) | WO2017173256A1 (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| ES2836743T3 (es) * | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| KR20230005428A (ko) | 2015-05-28 | 2023-01-09 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 진단 방법 |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3368571B1 (en) | 2015-10-30 | 2022-12-07 | The Regents of The University of California | Transforming growth factor-beta-responsive polypeptides and their methods for use |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| AU2017240801A1 (en) * | 2016-04-01 | 2018-10-25 | Amgen Inc. | Chimeric receptors to FLT3 and methods of use thereof |
| KR102427334B1 (ko) * | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| IL308831A (en) | 2016-04-08 | 2024-01-01 | Immunocore Ltd | T cell receptors |
| WO2018026953A1 (en) * | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018057585A1 (en) * | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
| US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3391907B8 (en) | 2017-04-20 | 2020-03-04 | iOmx Therapeutics AG | Intracellular kinase sik3 associated with resistance against anti-tumour immune responses, and uses thereof |
| PL3618842T3 (pl) | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komórkowej i związku immunomodulującego |
| BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| CN109748968B (zh) * | 2017-11-03 | 2020-12-01 | 西安宇繁生物科技有限责任公司 | Bcma特异性嵌合抗原受体t细胞及其应用 |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
| WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| CN109957021A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957016A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd38的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| US12280092B2 (en) | 2018-01-05 | 2025-04-22 | Nantbio, Inc. | Reprogrammed T cell-like NK cells |
| CA3090793C (en) * | 2018-02-16 | 2024-10-08 | Kite Pharma, Inc. | MODIFIED MULTIPOTENTED STEM CELLS, AND METHODS OF PREPARATION AND USE |
| US20210017277A1 (en) * | 2018-03-14 | 2021-01-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Anti-cd33 chimeric antigen receptors and their uses |
| WO2019202160A2 (en) | 2018-04-20 | 2019-10-24 | Iomx Therapeutics Ag | A 5-thiazolecarboxamide kinase inhibitor and uses thereof |
| US20200063100A1 (en) | 2018-05-11 | 2020-02-27 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR102734592B1 (ko) | 2018-06-01 | 2024-11-27 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 t 세포 요법 |
| CN112638428A (zh) * | 2018-06-12 | 2021-04-09 | H·李·莫菲特癌症中心和研究所公司 | 嵌合抗原受体肿瘤浸润淋巴细胞 |
| EP3806894A4 (en) * | 2018-06-12 | 2022-06-08 | Promab Biotechnologies, Inc. | PLAP-CAR EFFECTOR CELLS |
| CN110615843B (zh) | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| CN110623980A (zh) * | 2018-06-25 | 2019-12-31 | 深圳宾德生物技术有限公司 | 靶向cd38的嵌合抗原受体t细胞在自身免疫性疾病中的应用 |
| AU2019299555A1 (en) * | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| CN112805378A (zh) | 2018-08-09 | 2021-05-14 | 朱诺治疗学股份有限公司 | 用于评估整合核酸的方法 |
| WO2020052543A1 (en) * | 2018-09-10 | 2020-03-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cd33 and constructs thereof |
| WO2020072352A1 (en) * | 2018-10-01 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car-t cells targeting glioma stem cells for the treatment of glioblastoma multiforme |
| WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| US20210393691A1 (en) * | 2018-11-06 | 2021-12-23 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| EP3941938A1 (en) * | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| EP3959322A4 (en) * | 2019-04-22 | 2023-06-07 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3138633A1 (en) | 2019-04-30 | 2020-11-05 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| BR112021026832A2 (pt) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada |
| WO2021016091A1 (en) * | 2019-07-19 | 2021-01-28 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors for direct and indirect targeting of fibronectin-positive tumors |
| SG10201907378QA (en) * | 2019-08-08 | 2021-03-30 | Nat Univ Singapore | Genetically modified nk cells and uses thereof |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| AU2020382219A1 (en) | 2019-11-13 | 2022-05-12 | Crispr Therapeutics Ag | Manufacturing process for making T cells expressing chimeric antigen receptors |
| PH12022551160A1 (en) | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| MX2022005999A (es) | 2019-11-20 | 2022-06-17 | Gi Cell Inc | Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. |
| WO2021113776A1 (en) | 2019-12-06 | 2021-06-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods |
| US20230090117A1 (en) | 2020-01-28 | 2023-03-23 | Juno Therapeutics, Inc. | Methods for t cell transduction |
| CN111196858B (zh) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用 |
| JP2023519099A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用 |
| CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| US12649784B2 (en) | 2020-03-30 | 2026-06-09 | Oregon Health & Science University | Monoclonal antibodies for intracellular delivery of payloads |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| CA3181399A1 (en) | 2020-04-28 | 2021-11-04 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| CN111518219B (zh) | 2020-05-08 | 2021-06-22 | 浙江大学 | 嵌合性抗原受体及表达其的巨噬细胞、调节巨噬细胞极化的方法和应用 |
| EP4149952A1 (en) * | 2020-05-12 | 2023-03-22 | Institut Curie | Neoantigenic epitopes associated with sf3b1 mutations |
| KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| KR20230084470A (ko) | 2020-08-14 | 2023-06-13 | 카이트 파마 인코포레이티드 | 면역 세포 기능의 향상 |
| WO2022048314A1 (zh) * | 2020-09-03 | 2022-03-10 | 上海易慕峰生物科技有限公司 | 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用 |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| ES2962700T1 (es) * | 2020-10-12 | 2024-03-20 | Hpvvax Llc | Composición y método para tratar el cáncer, usando una vacuna como un primer ingrediente activo terapéutico en combinación con un segundo ingrediente activo |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| AU2021386370A1 (en) | 2020-11-24 | 2023-06-22 | Lyell Immunopharma, Inc. | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CA3203531A1 (en) | 2020-12-30 | 2022-07-07 | Simon Olivares | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| US20240168012A1 (en) | 2021-03-22 | 2024-05-23 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
| KR20230171994A (ko) | 2021-04-16 | 2023-12-21 | 셀진 코포레이션 | 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법 |
| CN118201618A (zh) | 2021-04-16 | 2024-06-14 | 细胞基因公司 | 与bcma定向t细胞疗法的组合疗法 |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| CN114121142B (zh) * | 2021-09-02 | 2023-10-31 | 四川大学华西医院 | 一种新型基因修饰增强型ny-eso-1特异型tcr-t模型构建方法及应用 |
| WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| US20240091261A1 (en) | 2022-08-26 | 2024-03-21 | Kite Pharma, Inc. | Immune cell function |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| US20260232729A1 (en) | 2023-02-03 | 2026-08-13 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| WO2024168192A1 (en) | 2023-02-10 | 2024-08-15 | Celgene Corporation | Assessment of bcma in biological samples |
| PE20260290A1 (es) | 2023-03-31 | 2026-02-10 | Abelzeta Inc | Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| EP4716851A2 (en) | 2023-05-23 | 2026-04-01 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| GB202317065D0 (en) | 2023-11-07 | 2023-12-20 | Coding Bio Ltd | BCMA binding molecules |
| WO2025147545A1 (en) | 2024-01-03 | 2025-07-10 | Juno Therapeutics, Inc. | Lipid nanoparticles for delivery of nucleic acids and related methods and uses |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202604957A (zh) * | 2024-05-03 | 2026-02-01 | 美商凱特製藥公司 | 嵌合受體及其使用方法 |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
| WO2026151982A1 (en) | 2025-01-10 | 2026-07-16 | Regeneron Pharmaceuticals, Inc. | Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7393531B2 (en) | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| NZ543635A (en) | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| CN102272153B (zh) | 2008-11-24 | 2015-04-15 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 高亲和力t细胞受体及其应用 |
| CN102421801B (zh) | 2009-03-10 | 2016-03-16 | 比奥根Ma公司 | 抗-bcma抗体 |
| JP5934099B2 (ja) * | 2009-10-01 | 2016-06-15 | アメリカ合衆国 | 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用 |
| MX2012005719A (es) | 2009-11-17 | 2012-07-30 | Basf Plant Science Co Gmbh | Plantas con rendimiento aumentado. |
| WO2011138414A1 (en) | 2010-05-05 | 2011-11-10 | Addex Pharma Sa | Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP3115373B1 (en) | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| EP2614143B1 (en) | 2010-09-08 | 2018-11-07 | Baylor College Of Medicine | Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells |
| US9845362B2 (en) * | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| CA2868121C (en) * | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| CN104395344B (zh) * | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| US9598489B2 (en) * | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| US10246505B2 (en) * | 2013-11-25 | 2019-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control HIV infection |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| BR112017000939A2 (pt) | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| ES2738705T3 (es) | 2014-09-19 | 2020-01-24 | Hope City | Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2 |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| CN107429253B (zh) | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| SG10201912519VA (en) * | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
| KR102427334B1 (ko) * | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| AU2017240801A1 (en) | 2016-04-01 | 2018-10-25 | Amgen Inc. | Chimeric receptors to FLT3 and methods of use thereof |
-
2017
- 2017-03-31 KR KR1020187031270A patent/KR102427334B1/ko active Active
- 2017-03-31 CN CN201780030898.9A patent/CN109328074A/zh active Pending
- 2017-03-31 TW TW109112511A patent/TWI787599B/zh active
- 2017-03-31 JP JP2018550787A patent/JP7034934B2/ja active Active
- 2017-03-31 SI SI201730928T patent/SI3436079T1/sl unknown
- 2017-03-31 SG SG10201912489QA patent/SG10201912489QA/en unknown
- 2017-03-31 PT PT17776766T patent/PT3436079T/pt unknown
- 2017-03-31 WO PCT/US2017/025351 patent/WO2017173256A1/en not_active Ceased
- 2017-03-31 ES ES17776766T patent/ES2891578T3/es active Active
- 2017-03-31 IL IL303785A patent/IL303785A/en unknown
- 2017-03-31 CA CA3019149A patent/CA3019149A1/en active Pending
- 2017-03-31 CU CU2018000121A patent/CU20180121A7/es unknown
- 2017-03-31 US US15/475,681 patent/US10603380B2/en active Active
- 2017-03-31 AR ARP170100823A patent/AR108427A1/es not_active Application Discontinuation
- 2017-03-31 PL PL17776766T patent/PL3436079T3/pl unknown
- 2017-03-31 TW TW111146001A patent/TW202313671A/zh unknown
- 2017-03-31 BR BR112018070073-8A patent/BR112018070073A2/pt not_active Application Discontinuation
- 2017-03-31 AU AU2017240667A patent/AU2017240667C1/en active Active
- 2017-03-31 EA EA201891965A patent/EA201891965A1/ru unknown
- 2017-03-31 PE PE2018001933A patent/PE20190173A1/es not_active Application Discontinuation
- 2017-03-31 CR CR20180461A patent/CR20180461A/es unknown
- 2017-03-31 SG SG11201808411RA patent/SG11201808411RA/en unknown
- 2017-03-31 KR KR1020227026040A patent/KR102584280B1/ko active Active
- 2017-03-31 IL IL261941A patent/IL261941B2/en unknown
- 2017-03-31 EP EP17776766.2A patent/EP3436079B1/en active Active
- 2017-03-31 MX MX2018012017A patent/MX391308B/es unknown
- 2017-03-31 TW TW106111228A patent/TWI691596B/zh active
- 2017-03-31 EP EP21192459.2A patent/EP3984559A1/en not_active Withdrawn
-
2018
- 2018-09-27 CL CL2018002762A patent/CL2018002762A1/es unknown
- 2018-09-27 PH PH12018550163A patent/PH12018550163A1/en unknown
- 2018-09-28 CO CONC2018/0010453A patent/CO2018010453A2/es unknown
- 2018-09-30 SA SA518400135A patent/SA518400135B1/ar unknown
- 2018-10-01 SV SV2018005756A patent/SV2018005756A/es unknown
- 2018-10-01 EC ECSENADI201873833A patent/ECSP18073833A/es unknown
- 2018-10-01 DO DO2018000213A patent/DOP2018000213A/es unknown
- 2018-10-01 MX MX2022003995A patent/MX2022003995A/es unknown
-
2019
- 2019-09-13 US US16/570,645 patent/US20200108142A1/en not_active Abandoned
- 2019-09-26 CL CL2019002739A patent/CL2019002739A1/es unknown
-
2021
- 2021-02-11 AR ARP210100357A patent/AR121318A2/es not_active Application Discontinuation
-
2022
- 2022-03-02 JP JP2022031538A patent/JP7379561B2/ja active Active
- 2022-06-23 AU AU2022204423A patent/AU2022204423A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515661A5 (enExample) | ||
| AU2015374296B2 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| JP2021520788A5 (enExample) | ||
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| JP2022523781A5 (enExample) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| RU2017105065A (ru) | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма | |
| HRP20221348T1 (hr) | Kimerni receptori i postupci njihove uporabe | |
| JP2026016490A (ja) | 二特異性形質導入エンハンサー | |
| JP2017527271A5 (enExample) | ||
| JP2017522879A5 (enExample) | ||
| JP2019516352A5 (enExample) | ||
| US20210128618A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| JP2023530704A5 (enExample) | ||
| JP2017507917A (ja) | 軟骨魚類由来の抗原認識ドメインを使用したキメラ抗原受容体 | |
| TW202122575A (zh) | 工程化的ｔ細胞及其產生方法 | |
| JP2023517063A5 (enExample) | ||
| JP2024539506A5 (enExample) | ||
| JP2021530233A5 (enExample) | ||
| KR20250121979A (ko) | 접착 분자 융합물을 디스플레이하는 입자 | |
| JP2023518930A5 (enExample) | ||
| JP2026500897A (ja) | 融合分子を呈示するレンチウイルス粒子およびその使用 | |
| WO2023217062A1 (zh) | 一种嵌合抗原受体及其应用 | |
| WO2025140265A1 (en) | Combination of chimeric antigen receptor and dap10 in cell therapy |